PanTera is a joint venture between IBA (Ion Beam Applications S.A.), the world leader in particle accelerator technology, and the Belgian Nuclear Research Centre SCK CEN, world leader in reactor produced medical radioisotopes. PanTera’s goal is to use the combined knowledge and expertise of IBA and SCK CEN, as well as the access they provide to the appropriate technology (Rhodotron electron accelerator) and materials (high purity radium-226 starting material), to secure the large-scale production of actinium-225 (Ac-225). This radioisotope is one of the most promising alpha-emitting radioisotopes to fight cancers and is the topic of >20 ongoing clinical trials for >10 different cancers. To support these clinical trials, PanTera has also secured an Early Supply of Ac-225 through a collaboration agreement with TerraPower Isotopes (TPI). Through this collaboration, PanTera will be able to supply already from 2024 onward over 30mCi of Ac-225 per week to support the development of radiotheranostic drugs.